A Study of belantamab mafodotin monotherapy in multiple myeloma participants with normal and varying degree of impaired renal function

Trial Identifier: 209626
Sponsor: GlaxoSmithKline
Collaborator:
Not applicable
Start Date: October 2020
Primary Completion Date: April 2025
Study Completion Date: March 2027
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
GREECE Athens, GREECE, 10676
GREECE Athens, GREECE, 11528
KOREA,_REPUBLIC_OF Busan, KOREA,_REPUBLIC_OF, 49241
KOREA,_REPUBLIC_OF Seoul, KOREA,_REPUBLIC_OF, 06591